Profil de fragilité excluant la dose complète de CHC-Bv dans l'ALCL: ECOG ≥3, OU (âge ≥75 avec G8 ≤14), O...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | RF-ALCL-FRAILTY-AGE |
|---|---|
| Type | Signal d’alerte |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-ALCL |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Origine du drapeau rouge
| Définition | Frailty profile precluding full-dose CHP-Bv in ALCL: ECOG ≥3, OR (age ≥75 with G8 ≤14), OR composite frailty (age ≥70 + Charlson ≥3 + albumin <3.5). Triggers de-escalation to brentuximab-vedotin monotherapy or attenuated CHP-Bv (50-75% doses). |
|---|---|
| Direction clinique | désescalade |
| Catégorie | âge de fragilité |
Logique de déclenchement
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"comparator": "<=",
"finding": "g8_score",
"threshold": 14
}
]
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 70
},
{
"comparator": ">=",
"finding": "charlson_score",
"threshold": 3
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.5
}
]
}
],
"type": "composite_score"
}
Notes
G8 (Geriatric-8) screening tool validated in oncology; ≤14 indicates need for full CGA. ALCL is unusual among PTCLs in that brentuximab monotherapy alone (1.8 mg/kg q3w) is meaningfully active in frail unfit patients (~40-60% ORR data extrapolated from r/r ALCL). Avoid vincristine + brentuximab combo when neuropathy already present. AlloHCT typically off-table; autoSCT consolidation post-CR remains reasonable in selected fit-elderly.
Utilisé par
No reverse references found in the YAML corpus.